Finally, this lipid-driven immunosuppressive mechanism induced by CD70-CD27 signaling opens CD70-targeted precision therapy as additional avenue for NPC patients, and is potentially feasible and effective in patients with melanoma, depending on their specific TME landscapes. This evidence concerns the gene CD27 and melanoma.